Recent Updates
Recently added Catalysts
LTRN Positive Sentiment

Lantern Pharma Receives Taiwan Approvals to Open Next Stage of Phase 2 HARMONIC™ Trial of LP-300 in Never-Smoker, EGFR-Mutant NSCLC

Wednesday, October 7, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Lantern Pharma has received necessary regulatory and IRB approvals in Taiwan to proceed with Part 2 of its Phase 2 HARMONIC™ trial for LP-300, targeting never-smoker, EGFR-mutant NSCLC patients. The Taiwan Food and Drug Administration approved the amended protocol in September, with local IRB approval following shortly after. This advancement marks a significant step in the trial's progression.

Market Sentiment Analysis

POSITIVE FACTORS

  • Regulatory approvals received in Taiwan for the trial.
  • Next stage of Phase 2 HARMONIC™ trial is now open.
  • AI-driven precision oncology approach shows promise.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+20%
120-day peak, hindsight
Typical move
4%
average across 5 past catalysts
Cash runway
~6 mo
High dilution risk
Lead asset
Tavocept in combination with cisplatin and either docetaxel or paclitaxel
Phase 3 · Non-small Cell Lung Cancer

Full Press Release Details

DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage, AI-driven precision oncology company, today announced that it has received regulatory and IRB approvals in Taiwan to open the next stage (Part 2) of its Phase 2 HARMONIC™ trial of LP-300. The Taiwan Food and Drug Administration (TFDA) approved the amended protocol earlier in September, and the lead Taiwan site received local Institutional Review Board (IRB) approval on September 29, 2026. The lead site is now open to

Frequently Asked Questions

What is the HARMONIC trial?

The HARMONIC trial is a Phase 2 clinical study evaluating LP-300 in patients with NSCLC.

What approvals did Lantern Pharma receive?

Lantern Pharma received regulatory and IRB approvals in Taiwan to proceed with the trial.

What is LP-300 targeting?

LP-300 is targeting never-smoker, EGFR-mutant non-small cell lung cancer (NSCLC) patients.

When was the IRB approval received?

The local Institutional Review Board approval was received on September 29, 2026.

ShareAdd on Google
Tags: LTRN Lantern Pharma LP-300 NSCLC Taiwan approvals EGFR-mutant
Last updated: Oct 7, 2026

Biotech snapshot

Cash runway
$7M liquidity · $1M/mo burn
~6 mo
High dilution risk
Lead asset
Tavocept in combination with cisplatin and either docetaxel or paclitaxelPhase 3
Non-small Cell Lung Cancer →

Catalyst track record

+20%
best trade around LTRN's most recent catalyst

Peak hindsight return over a 120-day window, across 5 tracked FDA/PDUFA catalysts for LTRN.

See every catalyst's timing & PoA →